170 related articles for article (PubMed ID: 21910869)
1. Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.
Davies JM; Trembath D; Deal AM; Funkhouser WK; Calvo BF; Finnegan T; Weck KE; Tepper JE; O'Neil BH
Radiat Oncol; 2011 Sep; 6():114. PubMed ID: 21910869
[TBL] [Abstract][Full Text] [Related]
2. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
3. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.
Gaedcke J; Grade M; Jung K; Schirmer M; Jo P; Obermeyer C; Wolff HA; Herrmann MK; Beissbarth T; Becker H; Ried T; Ghadimi M
Radiother Oncol; 2010 Jan; 94(1):76-81. PubMed ID: 19913317
[TBL] [Abstract][Full Text] [Related]
4. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
6. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
Hiramatsu M; Ninomiya H; Inamura K; Nomura K; Takeuchi K; Satoh Y; Okumura S; Nakagawa K; Yamori T; Matsuura M; Morikawa T; Ishikawa Y
Lung Cancer; 2010 Oct; 70(1):94-102. PubMed ID: 20117855
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
Yoon G; Lee H; Kim JH; Hur K; Seo AN
Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
[TBL] [Abstract][Full Text] [Related]
8. Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer.
Koyama FC; Lopes Ramos CM; Ledesma F; Alves VAF; Fernandes JM; Vailati BB; São Julião GP; Habr-Gama A; Gama-Rodrigues J; Perez RO; Camargo AA
Br J Surg; 2018 Jan; 105(2):e192-e203. PubMed ID: 29341150
[TBL] [Abstract][Full Text] [Related]
9. ARID3A Positivity Correlated With Favorable Prognosis in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy.
Yoon G; Park JY; Kim HJ; Choi GS; Kim JG; Kang BW; Kang MK; Seo AN
Anticancer Res; 2019 Jun; 39(6):2845-2853. PubMed ID: 31177122
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis.
Peng J; Lv J; Peng J
Int J Colorectal Dis; 2021 Aug; 36(8):1781-1790. PubMed ID: 33760952
[TBL] [Abstract][Full Text] [Related]
11. Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT mutations and high tumour mutational burden.
Stockton JD; Tee L; Whalley C; James J; Dilworth M; Wheat R; Nieto T; ; Geh I; Barros-Silva JD; Beggs AD
Radiat Oncol; 2021 Jul; 16(1):129. PubMed ID: 34256782
[TBL] [Abstract][Full Text] [Related]
12. CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways.
Schulte SL; Waha A; Steiger B; Denkhaus D; Dörner E; Calaminus G; Leuschner I; Pietsch T
Oncotarget; 2016 Aug; 7(34):55026-55042. PubMed ID: 27391150
[TBL] [Abstract][Full Text] [Related]
13. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
14. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.
Holck S; Bonde J; Pedersen H; Petersen AA; Chaube A; Nielsen HJ; Larsson LI
Hum Pathol; 2016 Aug; 54():37-46. PubMed ID: 27036313
[TBL] [Abstract][Full Text] [Related]
15. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.
Price TJ; Hardingham JE; Lee CK; Weickhardt A; Townsend AR; Wrin JW; Chua A; Shivasami A; Cummins MM; Murone C; Tebbutt NC
J Clin Oncol; 2011 Jul; 29(19):2675-82. PubMed ID: 21646616
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population.
El Otmani I; El Agy F; El Baradai S; Bouguenouch L; Lahmidani N; El Abkari M; Benajah DA; Toughrai I; El Bouhaddouti H; Mouaqit O; Ibn Majdoub Hassani K; Mazaz K; Benjelloun EB; Ousadden A; El Rhazi K; Bouhafa T; Benbrahim Z; Ouldim K; Ibrahimi SA; Ait Taleb K; Chbani L
Dis Markers; 2020; 2020():8459303. PubMed ID: 31998419
[TBL] [Abstract][Full Text] [Related]
17. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
[TBL] [Abstract][Full Text] [Related]
18. High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.
Wang CY; Deng JY; Cai XW; Fu XL; Li Y; Zhou XY; Wu XH; Hu XC; Fan M; Xiang JQ; Zhang YW; Chen HQ; Perez R; Jiang GL; Zhao KL
Oncotarget; 2015 Jul; 6(21):18674-82. PubMed ID: 26124180
[TBL] [Abstract][Full Text] [Related]
19. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
20. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
